Literature DB >> 19587055

Human immunodeficiency virus type 1 nucleocapsid inhibitors impede trans infection in cellular and explant models and protect nonhuman primates from infection.

Gregory S Wallace1, Cecilia Cheng-Mayer, Marco L Schito, Patricia Fletcher, Lisa M Miller Jenkins, Ryo Hayashi, A Robert Neurath, Ettore Appella, Robin J Shattock.   

Abstract

Here, we report that the S-acyl-2-mercaptobenzamide thioester (SAMT) class of human immunodeficiency virus type 1 (HIV-1) nucleocapsid protein (NCp7) inhibitors was able to prevent transmission of HIV-1 from infected cells, including primary cells. Furthermore, when SAMTs were introduced during an HIV-1 challenge of cervical explant tissue, inhibition of dissemination of infectious virus by cells emigrating from the tissue explants was observed. Preliminary studies using a rhesus macaque vaginal challenge model with mixed R5 and X4 simian-human immunodeficiency virus infection found that five of six monkeys were completely protected, with the remaining animal being partially protected, infected only by the R5 virus. These data suggest that SAMTs may be promising new drug candidates for further development in anti-HIV-1 topical microbicide applications.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19587055      PMCID: PMC2738238          DOI: 10.1128/JVI.00820-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  Analysis of NCp7-dependent activation of HIV-1 cDNA integration and its conservation among retroviral nucleocapsid proteins.

Authors:  Leonora Poljak; Susan M Batson; Damien Ficheux; Bernard P Roques; Jean-Luc Darlix; Emmanuel Käs
Journal:  J Mol Biol       Date:  2003-06-06       Impact factor: 5.469

2.  Synthetic cervical mucus formulation.

Authors:  Bríd T Burruano; Roger L Schnaare; Daniel Malamud
Journal:  Contraception       Date:  2002-08       Impact factor: 3.375

3.  Multiple effects of an anti-human immunodeficiency virus nucleocapsid inhibitor on virus morphology and replication.

Authors:  L Berthoux; C Péchoux; J L Darlix
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

4.  Misuse of standard error of the mean (SEM) when reporting variability of a sample. A critical evaluation of four anaesthesia journals.

Authors:  P Nagele
Journal:  Br J Anaesth       Date:  2003-04       Impact factor: 9.166

Review 5.  Topical microbicides to prevent HIV: clinical drug development challenges.

Authors:  Craig W Hendrix; Ying Jun Cao; Edward J Fuchs
Journal:  Annu Rev Pharmacol Toxicol       Date:  2009       Impact factor: 13.820

6.  A human immunodeficiency virus-transgenic mouse model for assessing interventions that block microbial-induced proviral expression.

Authors:  M L Schito; P E Kennedy; R P Kowal; E A Berger; A Sher
Journal:  J Infect Dis       Date:  2001-05-01       Impact factor: 5.226

7.  In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission.

Authors:  Charlene S Dezzutti; V Nicole James; Artur Ramos; Sharon T Sullivan; Aladin Siddig; Timothy J Bush; Lisa A Grohskopf; Lynn Paxton; Shambavi Subbarao; Clyde E Hart
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

8.  In vivo antiviral activity of novel human immunodeficiency virus type 1 nucleocapsid p7 zinc finger inhibitors in a transgenic murine model.

Authors:  Marco L Schito; Atul Goel; Yongsheng Song; John K Inman; Rasem J Fattah; William G Rice; Jim A Turpin; Alan Sher; Ettore Appella
Journal:  AIDS Res Hum Retroviruses       Date:  2003-02       Impact factor: 2.205

9.  Human immunodeficiency virus type 1 nucleocapsid zn(2+) fingers are required for efficient reverse transcription, initial integration processes, and protection of newly synthesized viral DNA.

Authors:  James S Buckman; William J Bosche; Robert J Gorelick
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

10.  Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue.

Authors:  Qinxue Hu; Ines Frank; Vennansha Williams; John J Santos; Patricia Watts; George E Griffin; John P Moore; Melissa Pope; Robin J Shattock
Journal:  J Exp Med       Date:  2004-04-12       Impact factor: 14.307

View more
  21 in total

Review 1.  Secretory IgA: arresting microbial pathogens at epithelial borders.

Authors:  Nicholas J Mantis; Stephen J Forbes
Journal:  Immunol Invest       Date:  2010       Impact factor: 3.657

2.  A one-pot preparation of N-2-mercaptobenzoyl-amino amides.

Authors:  Robert J Bahde; Daniel H Appella; William C Trenkle
Journal:  Tetrahedron Lett       Date:  2011-08-10       Impact factor: 2.415

Review 3.  Mucosal HIV-1 transmission and prevention strategies in BLT humanized mice.

Authors:  Paul W Denton; J Victor Garcia
Journal:  Trends Microbiol       Date:  2012-04-12       Impact factor: 17.079

Review 4.  Role of HIV-1 nucleocapsid protein in HIV-1 reverse transcription.

Authors:  Judith G Levin; Mithun Mitra; Anjali Mascarenhas; Karin Musier-Forsyth
Journal:  RNA Biol       Date:  2010-11-01       Impact factor: 4.652

5.  Delay of simian human immunodeficiency virus infection and control of viral replication in vaccinated macaques challenged in the presence of a topical microbicide.

Authors:  Cecilia Cheng-Mayer; Yaoxing Huang; Agegnehu Gettie; Lily Tsai; Wuze Ren; Madina Shakirzyanova; Silvana T Sina; Nataliya Trunova; James Blanchard; Lisa M Miller Jenkins; Yungtai Lo; Marco L Schito; Ettore Appella
Journal:  AIDS       Date:  2011-09-24       Impact factor: 4.177

Review 6.  HIV type 1 Gag as a target for antiviral therapy.

Authors:  Abdul A Waheed; Eric O Freed
Journal:  AIDS Res Hum Retroviruses       Date:  2011-09-21       Impact factor: 2.205

Review 7.  Advances in targeting nucleocapsid-nucleic acid interactions in HIV-1 therapy.

Authors:  Divita Garg; Bruce E Torbett
Journal:  Virus Res       Date:  2014-07-12       Impact factor: 3.303

8.  An Intravaginal Ring for the Simultaneous Delivery of an HIV-1 Maturation Inhibitor and Reverse-Transcriptase Inhibitor for Prophylaxis of HIV Transmission.

Authors:  Shweta R Ugaonkar; Justin T Clark; Lexie B English; Todd J Johnson; Karen W Buckheit; Robert J Bahde; Daniel H Appella; Robert W Buckheit; Patrick F Kiser
Journal:  J Pharm Sci       Date:  2015-07-06       Impact factor: 3.534

Review 9.  HIV-1 gag: an emerging target for antiretroviral therapy.

Authors:  Philip R Tedbury; Eric O Freed
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

10.  An SAMT-247 Microbicide Provides Potent Protection against Intravaginal Simian Immunodeficiency Virus Infection of Rhesus Macaques, whereas an Added Vaccine Component Elicits Mixed Outcomes.

Authors:  Sabrina Helmold Hait; Christopher James Hogge; Mohammad Arif Rahman; Eun-Ju Ko; Ruth Hunegnaw; Zuena Mushtaq; Gospel Enyindah-Asonye; Tanya Hoang; Lisa M Miller Jenkins; Ettore Appella; Daniel H Appella; Marjorie Robert-Guroff
Journal:  J Immunol       Date:  2020-05-11       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.